Introduction {#s1}
============

Centrioles are microtubule-based, ninefold symmetrical structures essential for centrosome and cilia formation. In cycling cells, centrioles are maintained in fixed numbers, and formed through canonical duplication depending on pre-existing (or mother) centrioles. In the absence of pre-existing centrioles, however, de novo synthesis can occur ([@bib14]). The number of centrioles formed through the de novo pathway is highly variable ([@bib14]; [@bib17]), providing an explanation for why canonical duplication dominates in dividing cells. In contrast to cycling cells, in post-mitotic cells such as multi-ciliated epithelia, the genes required for centriole assembly are highly up-regulated ([@bib11]) to produce large, variable numbers of centrioles prior to ciliogenesis, a process thought to primarily depend on de novo assembly ([@bib8]). Interestingly, a recent study showed that the production of high quantities of centrioles in mouse multi-ciliated epithelia is in fact driven by the pre-existing centriole rather than through de novo assembly ([@bib2]), suggesting that the presence of pre-existing centrioles may have additional roles other than the number control for centriole biogenesis.

Centriole biogenesis, canonical or de novo, starts with cartwheel assembly, a geometric scaffold that defines the shape and structural integrity of centrioles ([@bib3]). The backbone of the cartwheel is characterized by a central hub from which nine spokes emanate ([@bib3]) and is primarily made of the centriolar protein SAS-6 ([@bib15]; [@bib23]). SAS-6 exists as dimers, which can self-oligomerize in vitro via an N-terminal head domain, forming a ring resembling the central hub, and C-terminal tails pointing outwards as spokes ([@bib15]; [@bib23]; [@bib24]), albeit not always ninefold symmetric in vitro([@bib6]). Nevertheless, these elegant discoveries raise an exciting proposal that the self-assembly property associated with the N terminus of SAS-6 drives cartwheel and centriole formation.

In contrast to the SAS-6 self-assembly model, a template-based assembly model, dependent on the interaction of the C-terminal tail of SAS-6 with the lumen of mother centrioles, has recently been proposed to initiate canonical duplication ([@bib9]). During S phase, SAS-6 molecules are first recruited to the proximal lumen of the mother centriole prior to centriole duplication, adopting a cartwheel-like organization through interactions with the luminal wall, rather than via their self-oligomerization activity. This leads to a proposal that mother centrioles may function as the template to shape SAS-6 assembly, thereby preserving the geometric shape of the centriole that otherwise cannot be ensured by SAS-6 self-assembly alone. Notably, the template-based model appears incompatible with de novo centriole synthesis in which no pre-existing centrioles are required. However, as the nature of de novo synthesis, for example, whether it is indeed based on SAS-6 self-assembly, has not been determined, it is premature to accept or reject any of these ideas.

Results {#s2}
=======

Reconstitution of de novo centrosome synthesis in human cells {#s2-1}
-------------------------------------------------------------

To characterize de novo formation of centrioles or centrosomes, we used CRISPR/Cas9 gene targeting to sequentially inactivate p53 and SAS-6 genes in retinal pigment epithelial cells (RPE1), generating stable, acentriolar cell lines (*SAS-6^-/-^; p53^-/-^*) in which de novo centrosome formation can be subsequently reconstituted ([@bib13]) (see 'Materials and methods'). Pure acentriolar cell lines were established through clonal propagation from single cells, a process taking 4--5 weeks, before these cells were used for experiments. In two independent *SAS-6^-/-^; p53^-/-^* cell lines we generated (clone \#1 and \#2), frameshift mutations present in the beginning of the coding region were found in each SAS-6 allele ([Figure 1---figure supplement 1A](#fig1s1){ref-type="fig"}), predicting to produce severely truncated products consisting of 19 or 23 amino acids in clone \#1 or \#2, respectively. Consistently, Western blot analyses using antibodies against either the N- or C-terminal region of SAS-6 failed to detect any SAS-6 signal in these cells ([Figure 1B](#fig1){ref-type="fig"}; [Figure 1---figure supplement 1C](#fig1s1){ref-type="fig"}). Similar frameshift mutations were also seen in TP53 alleles ([Figure 1---figure supplement 1B](#fig1s1){ref-type="fig"}), leading to loss of p53 function ([@bib13]). Importantly, both SAS-6 knockout cell lines completely lack centrioles or centrosomes as expected ([Figure 1A](#fig1){ref-type="fig"} for clone \#1; [Figure 1---figure supplement 2A](#fig1s2){ref-type="fig"} for clone \#2), but can continue to proliferate in the absence of p53 ([Figure 1C](#fig1){ref-type="fig"} for clone \#1; [Figure 1---figure supplement 2B](#fig1s2){ref-type="fig"} for clone \#2) ([@bib5]; [@bib13]; [@bib18]; [@bib26]), although their M phase is significantly lengthened ([Figure 1D](#fig1){ref-type="fig"}). Intriguingly, when exogenous wild-type, full length SAS-6 (SAS-6^FL^) was inducibly expressed in SAS-6^-/-^ cells (see 'Materials and methods' for details), either in clone \#1 or \#2, variable numbers of centrosomes formed robustly in the absence of pre-existing centrosomes ([Figure 1E,G](#fig1){ref-type="fig"} for clone \#1; [Figure 1---figure supplement 2C,D](#fig1s2){ref-type="fig"} for clone \#2), a result consistent with previous reports ([@bib18]; [@bib26]). As clone \#1 and clone \#2 cell lines behave similarly, we used clone \#1 to establish a stable, cell-based system in which the role of SAS-6 in de novo centrosome synthesis can be analyzed (see below).10.7554/eLife.10586.003Figure 1.De novo centrosome formation in the absence of SAS-6 self-oligomerization. (**A**) Wild-type (WT) or acentrosomal (*p53^-/-^; SAS-6 ^-/-^*; clone \#1) RPE1 cells were stained with anti-centrin (green) and γ-tubulin (red). DNA (DAPI, blue). (**B**) Western blot analysis of WT or SAS-6^-/-^ cells with indicated antibodies, including both N- and C-terminal SAS-6 antibodies (SAS-6N; SAS-6C). (**C**) WT or acentrosomal cells in mitosis were stained with anti-centrin (green), α-tubulin (red), and pericentrin (blue). (**D**) The duration of mitosis in WT or SAS-6^-/-^ cells was measured through time-lapse imaging of live cells. (**E**) A schematic diagram showing various SAS-6 mutants tagged with Flag and HA (FH). Clone \#1 *p*53^-/-^ *SAS*-6^-/-  ^cells were infected with lentiviruses carrying various of SAS-6 constructs, and the ability of each construct in rescuing centrosome formation was indicated and quantified in infected cells expressing detectable HA-tagged SAS-6. n, number of infected cells examined. (**F**) Isogenic *SAS*-6^-/-^;  *p*53^-/-^  cells carrying indicated SAS-6 constructs (see Methods) were induced for SAS-6 expression for 3 days and then analyzed by western blot with Flag antibodies or C-terminal SAS-6 antibodies (SAS-6C). For analyses with N-terminal SAS-6 antibodies (SAS-6N), please see [Figure 1---figure supplement 1D](#fig1s1){ref-type="fig"}. Note that in Flag staining, DM6 leaked to the lane of DM5. The expression level of each SAS-6 construct, indicated as fold changes (Folds) relative to the endogenous SAS-6 or SAS-6^FL^, is shown. (**G**) Isogenic *SAS*-6^-/-^;  *p*53^-/-^ cells carrying indicated SAS-6 constructs were treated as (**F**) and analyzed by immunofluorescence microscopy using indicated antibodies (Scale bar: 20 μm in **A** and **G**, 10 μm in **C**).**DOI:** [http://dx.doi.org/10.7554/eLife.10586.003](10.7554/eLife.10586.003)10.7554/eLife.10586.004Figure 1---figure supplement 1.Characterization of *SAS*6^-/-^; *p*53^-/-^ cell lines (clone \#1 and \#2).(**A, B**) Sequence analyses of SAS-6 and p53 alleles in clone \#1 and clone \#2 as indicated. The sequence of wild-type and edited alleles are in black and blue, respectively. The lesion (deletion or insertion) is shown in red. (**C**) Western blot analysis of WT, *SAS6^-/-^; p53^-/-^* clone \#1, and *SAS6^-/-^; p53^-/-^* clone \#2 cells with indicated antibodies. SAS-6C and SAS-6N are antibodies recognizing the N-terminus and C-terminus of SAS-6, respectively. (**D**) Isogenic *SAS6^-/-^; p53^-/-^* cells carrying indicated SAS-6 constructs (see 'Methods') were induced to express indicated SAS-6 mutants for 3 days as in [Figure 1F](#fig1){ref-type="fig"}, and then processed for Western blot with N-terminal SAS-6 antibodies (SAS-6N), Flag antibodies, and tubulin antibodies as the loading control. The expression level of each SAS-6 construct, indicated as fold changes (Folds) relative to the endogenous SAS-6 or SAS-6^FL^, is shown.**DOI:** [http://dx.doi.org/10.7554/eLife.10586.004](10.7554/eLife.10586.004)10.7554/eLife.10586.005Figure 1---figure supplement 2.Induction of de novo centrosome formation in clone \#2 *SAS*6^-/-^; *p*53^-/-^ cells in the absence of SAS-6 self-oligomerization.(**A, B**) Wild-type (WT) or clone \#2 acentrosomal (*p53^-/-^; SAS-6 ^-/-^*) RPE1 cells were stained with indicated antibodies during interphase (**A**) and mitosis (**B**). DNA (DAPI, blue). (**C, D**) Clone \#2 acentrosomal cells were infected with lentiviruses, and induced to express indicated SAS-6 constructs for 16h (**C**) or 3 days (**D**). The ability of each SAS-6 mutant in rescuing de novo centriole (**C**) or centrosome (**D**) formation was examined with indicated antibodies. HA staining marks SAS-6.**DOI:** [http://dx.doi.org/10.7554/eLife.10586.005](10.7554/eLife.10586.005)

SAS-6 self-oligomerization is not required for de novo centrosome formation {#s2-2}
---------------------------------------------------------------------------

To determine which domains of SAS-6 is required and sufficient for de novo centrosome formation, full length SAS-6 (FL) or various SAS-6 deletion mutants (DMs) were made to allow controlled expression under the doxycycline inducible promoter ([Figure 1E](#fig1){ref-type="fig"}). Isogenic, acentriolar *SAS-6^-/-^; p53^-/- ^*cell lines stably carrying specific SAS-6 expression constructs were isolated in the absence of doxycycline (see Methods). Upon induction by doxycycline treatments ([Figure 1F](#fig1){ref-type="fig"}; [Figure 1---figure supplement 1D](#fig1s1){ref-type="fig"}), the ability of each SAS-6 mutant in driving de novo centrosome formation was examined ([Figure 1G](#fig1){ref-type="fig"}). Note that similar results were also seen in reconstitution experiments done in non-isogenic condition ([Figure 1E](#fig1){ref-type="fig"}; [Figure 1---figure supplement 2](#fig1s2){ref-type="fig"}). All SAS-6 fragments lacking the C-terminal domain (DM1, DM3, and DM5) failed to induce any centrosome formation ([Figure 1E,G](#fig1){ref-type="fig"}), although expressed at similar or higher levels ([Figure 1F](#fig1){ref-type="fig"}; [Figure 1---figure supplement 1D](#fig1s1){ref-type="fig"}). The C-terminal tail alone (DM6) was also insufficient. However, when the full-length coiled-coil domain (DM2) or a small portion of it (DM4) was present together with the C-terminal tail, it effectively drove de novo centrosome formation in all cells ([Figure 1E,G](#fig1){ref-type="fig"}; 100). Consistently, SAS-6 harboring the F131E mutation (F131E) that has been previously shown to disrupt the oligomerization property of SAS-6 ([@bib15]; [@bib23]) also efficiently drove de novo centrosome formation ([Figure 1E--G,](#fig1){ref-type="fig"}100%), with an expression level slightly higher than the endogenous level ([Figure 1F](#fig1){ref-type="fig"}; [Figure 1---figure supplement 1D](#fig1s1){ref-type="fig"}). A recent report showed that the fly SAS6 mutant equivalent to human SAS-6^F131E^ could support the formation of some centriole-like structures in vivo ([@bib7]). Our result thus suggests that in contrary to the SAS-6 self-assembly model, the main activity of SAS-6 in promoting centriole assembly is possessed by its C-terminal portion, rather than the N-terminal domain mediating SAS-6 self-oligomerization.

Centrioles formed in the absence of SAS-6 self-oligomerization can duplicate and ciliate {#s2-3}
----------------------------------------------------------------------------------------

To determine whether centrioles form the core of these de novo centrosomes, SAS-6^-/-^ cells arrested in S phase were induced to express various types of SAS-6 mutants, and examined for de novo centriole assembly (see 'Materials and methods'). Consistently, FL, F131E, DM2, and DM4, all of which contain intact C-termini, efficiently induced the formation of de novo centrioles in all cells (100%), as revealed by the co-localization of centrin, SAS-6, STIL, CEP135, and CPAP ([Figure 2](#fig2){ref-type="fig"}; [Figure 2---figure supplement 1](#fig2s1){ref-type="fig"}). Moreover, some of these de novo centrioles, even those formed with DM4 that lacks the entire N-terminal half of SAS-6, could later mature properly by acquiring distal appendages. Importantly, upon G1 arrest, some of these mature centrioles were able to support ciliogenesis ([Figure 2B](#fig2){ref-type="fig"}), suggesting that functionally normal centrioles can arise from de novo assembly through SAS-6 mutants that are incapable of self-oligomerization.10.7554/eLife.10586.006Figure 2.De novo centrioles formed in the absence of SAS-6 self-oligomerization can ciliate and duplicate. (**A**) Isogenic *SAS-6^-/-^; p53^-/-^* cells carrying indicated SAS-6 constructs (see 'Methods') were arrested in S phase and induced to express indicated SAS-6 mutants for 16 hr and then immunostained with indicated antibodies to visualize de novo centrioles (centrin, green; SAS-6/HA, red). DNA (DAPI, blue). (**B**) Isogenic *SAS-6^-/-^; p53^-/-^* cells carrying indicated SAS-6 constructs (see 'Methods') were induced to express indicated SAS-6 mutants for 3 days, arrested in G1 for additional 36 hr, and then processed for immunofluorescence microscopy to visualize cilia (GT335, green) and distal appendage (CEP164, red). DNA (DAPI, blue). (**C**) Isogenic *SAS-6^-/-^; p53^-/-^* cells carrying indicated SAS-6 constructs (see 'Methods') were induced to express indicated SAS-6 mutants for 3 days, and then processed for BrdU pulse-chase before fixation for immunofluorescence. Centriole duplication was revealed with indicated antibodies (centrin, green; daughter centriole marker, STIL, red; PCM marker, γ-tubulin, blue). S-phase cells labeled with BrdU were shown (blue). (**D**) Quantification of the centriole duplication efficiency from (**C**). S-phase cells were identified (BrdU+) and their centrioles were analyzed by immunofluorescence with centrin, STIL, and γ-tubulin antibodies. Error bars represent standard error of the mean (SEM); n \> 150, N = 3.**DOI:** [http://dx.doi.org/10.7554/eLife.10586.006](10.7554/eLife.10586.006)10.7554/eLife.10586.007Figure 2---figure supplement 1.Characterization of de novo centrioles formed in the absence of SAS-6 self-oligomerization.*p53^-/-^; SAS-6 ^-/-^* cells (clone \#1) exogenously expressing full-length SAS-6 (FL) or various SAS-6 mutants as indicated were analyzed by immunofluorescence with indicated antibodies.**DOI:** [http://dx.doi.org/10.7554/eLife.10586.007](10.7554/eLife.10586.007)

We next examine whether de novo centrioles formed with F131E or DM4 can later support canonical duplication in S phase after they have been converted to centrosomes ([@bib25]). Strikingly, both F131E- and DM4-derived centrioles could duplicate, as revealed by centrin and STIL staining, with an efficiency grossly similar to or only slightly less than that of centrioles derived from wild-type SAS-6 ([Figure 2C,D](#fig2){ref-type="fig"}). This result, however, appears inconsistent with previous reports, where neither F131E nor DM4 could fully support centriole duplication ([@bib9]; [@bib15]; [@bib23]), although both were able to initiate SAS-6/cartwheel assembly in the presence of pre-existing centrioles ([@bib9]). We do not understand the reason behind this discrepancy, but the result that F131E or DM4 can support the duplication of F131E- or DM4-derived centrioles, respectively ([Figure 2C,D](#fig2){ref-type="fig"}), but not pre-existing, wild-type SAS-6-derived centrioles ([@bib9]; [@bib15]; [@bib23]) raises an idea that perhaps pre-existing centrioles have an active, dominant role in guiding canonical duplication.

Ninefold symmetric centrioles can form in the absence of SAS-6 self-oligomerization {#s2-4}
-----------------------------------------------------------------------------------

As SAS-6 self-oligomerization is also thought to define the ninefold symmetric shape of centrioles, it is possible that de novo centrioles derived from F131E or DM4 can function normally as centrosomes or basal bodies, but their shape or structural integrity may be defective. To determine the structural integrity of de novo centrioles, serial sectioning transmission electron microscopy (TEM) was used to analyze SAS-6^-/-^ cells inducibly expressing FL, F131E or DM4. To our surprise, normal looking centrioles, which are characterized as 200 nm x 500 nm in size, made of nine microtubule triplets, and equipped with distal and sub-distal appendages, could be easily found in cells expressing either F131E or DM4 ([Figure 3A--C](#fig3){ref-type="fig"}). In particular, EM tomography reconstruction of a centriole from DM4 expressing cells revealed a perfect ninefold symmetric shape ([Figure 3B](#fig3){ref-type="fig"}; [Video 1](#video1){ref-type="other"}). Moreover, EM analyses also confirmed that at least some DM4-derived centrioles could ciliate ([Figure 3C](#fig3){ref-type="fig"}) and duplicate ([Figure 3D](#fig3){ref-type="fig"}), firmly demonstrating that neither structural assembly nor shape determination of centrioles strictly depends on the self-oligomerization activity of SAS-6. Rather, the C-terminal half of SAS-6 is both required and sufficient for centriole biogenesis.10.7554/eLife.10586.008Figure 3.SAS-6 self-assembly is not essential for the ninefold symmetry of centrioles.Isogenic *SAS-6^-/-^; p53^-/-^* cells carrying indicated SAS-6 constructs (see 'Methods') were induced to express indicated SAS-6 mutants for 3 days, and then processed for serial sectioning electron microscopy. (**A,B**) Mature canonical centrioles in WT RPE1 cells, or de novo centrioles formed in SAS6^-/- ^cells expressing full-length (FL) or mutant SAS-6 as indicated are shown in longitudinal (**A**) or cross sectional (**B**) views. Note that these centrioles were mature and have acquired appendages. (**C**) Ciliated centrioles from indicated cell types were serially sectioned and examined by EM. (**D**) Duplicated, engaged centriole pairs from indicated cell types were serially sectioned and examined by EM. Scale bar: 200 nm.**DOI:** [http://dx.doi.org/10.7554/eLife.10586.008](10.7554/eLife.10586.008)Video 1.EM tomography of a normal centriole from SAS-6^DM4^ expressing cells (related to [Figure 3](#fig3){ref-type="fig"}).Note that a centriole on the right in cross-sectional views contains nine MT triplets.**DOI:** [http://dx.doi.org/10.7554/eLife.10586.009](10.7554/eLife.10586.009)10.7554/eLife.10586.009

De novo centriole assembly is an error-prone process {#s2-5}
----------------------------------------------------

While SAS-6 self-assembly is not essential for centriole biogenesis, structurally normal centrioles can indeed form in the absence of pre-existing centrioles, questioning the necessity of having mother centrioles in canonical duplication. We thus asked if the defect-free rate of de novo centriole production is comparable to that of canonical duplication. EM analyses revealed that canonically duplicated centrioles are essentially free of error in their size, structural integrity, and geometric shape ([Figure 4E](#fig4){ref-type="fig"}, 100%, n = 70). In striking contrast, we consistently observed a small but significant portion of de novo centrioles that are abnormal, including centrioles missing variable numbers of MT triplets, or varying in size or shape ([Figure 4A--D](#fig4){ref-type="fig"}; [Video 2](#video2){ref-type="other"}). Importantly, similar types of abnormalities were seen regardless of whether centrioles were derived from SAS-6^FL^, SAS-6^F131E^, or SAS-6^DM4^. Nevertheless, these abnormally looking centrioles appeared to have normal activities, suggesting that they are not simply unstable structures in the process of non-specific disintegration. For example, we observed SAS-6^FL^-derived centrioles that had only six MT triplets, but able to duplicate, producing daughter centrioles also made of an incomplete set of MT triplets ([Figure 4A-\#1](#fig4){ref-type="fig"}). SAS-6^FL^-derived centrioles that appeared larger than normal centrioles ([Figure 4A-\#2](#fig4){ref-type="fig"}), but able to mature and acquire appendages were also found. In addition, we observed SAS-6^FL^-derived centrioles made of disorganized MT triplets ([Figure 4A-\#3](#fig4){ref-type="fig"}), or centrioles comprising of 9 MT triplets but existing as a distorted open cylinder ([Figure 4A-\#6](#fig4){ref-type="fig"}). Consequently, the width (outer diameter) of SAS-6^FL^-derived centrioles is more variable than that of canonically duplicated centrioles ([Figure 4D](#fig4){ref-type="fig"}). De novo centrioles made of disorganized, or abnormal numbers of, MT triplets have also been seen to form in cells depleted of the endogenous centrioles by laser ablation ([@bib17]).10.7554/eLife.10586.010Figure 4.Centrioles formed through de novo assembly are error-prone.(**A--C**) Isogenic *SAS-6^-/-^; p53^-/-^* cells carrying indicated SAS-6 constructs (see 'Methods') were induced to express indicated SAS-6 mutants for 3 days, and then processed for serial sectioning electron microscopy. (**A1**) A mature, SAS-6^FL^-derived centriole missed three MT triplets but was able to duplicate, producing daughter centrioles also made of an incomplete set of MT triplets (see stars in sections I and II). It appears that two daughter centrioles were formed at the same time. (**A2**) A mature, SAS-6^FL^-derived centriole 33% wider than normal centrioles was able to acquire appendages. (**A3**) A SAS-6^FL^-derived centriole made of disorganized MTs. (**A4&5**) Cross-sectional views of SAS-6^FL^-derived, abnormal centrioles missing MT triplets. (**A6**) A SAS-6^FL^-derived centriole carrying 9 MT triplets (arrow heads) but existing as a distorted open cylinder (arrow). (**B**) Abnormal centrioles derived from SAS-6^DM4^ were shown in cross-sectional or longitudinal views. (**C**) Abnormal centrioles derived from SAS-6^F131E^ were shown in cross-sectional views. Note that a larger centriole made of 11 MT triplets was shown (**C1**). (**D**) The outer diameter of centrioles was quantified for both canonical centrioles (in normal RPE1 cells), and SAS-6^FL^-derived de novo centrioles. (**E**) Quantifications showing the error rates of de novo and canonical centrioles. Sample size (n) is indicated. Note that arrows in all images indicate the missing of MT triplets.**DOI:** [http://dx.doi.org/10.7554/eLife.10586.010](10.7554/eLife.10586.010)Video 2.EM tomography of an abnormal centriole from SAS-6^DM4^ expressing cells (related to [Figure 4](#fig4){ref-type="fig"}).Note that a centriole on the right in cross-sectional views contains eight MT triplets.**DOI:** [http://dx.doi.org/10.7554/eLife.10586.011](10.7554/eLife.10586.011)10.7554/eLife.10586.011

Similarly, abnormal centrioles were observed in the population of F131E- or DM4- derived centrioles, including smaller/incomplete centrioles ([Figure 4B,C](#fig4){ref-type="fig"}), or bigger centrioles that were made of more than nine MT triplets ([Figure 4C-\#1](#fig4){ref-type="fig"}). Notably, DM4-mediated, but not F131E-mediated, de novo synthesis clearly has an error rate higher than those mediated by SAS-6^FL^ ([Figure 4E](#fig4){ref-type="fig"}), suggesting that the N-terminal half of SAS-6 is involved in some additional processes that ensure the accuracy or quality control of centriole assembly. Taken together, these results suggest that in the absence of pre-existing centrioles, de novo centriole synthesis can occur, largely independent of SAS-6 self-oligomerization, but the process is inherently error-prone, and may require the presence of pre-existing centrioles to achieve high accuracy.

Discussion {#s3}
==========

We have established a cell-based system for reconstitution of de novo centriole assembly in human cells. Using this system, we found that self-oligomerization of SAS-6, an activity proposed to drive cartwheel/centriole formation, is in fact not essential for the structural assembly or shape determination of centrioles. Instead, de novo centriole formation can be sufficiently driven by the C-terminal half of SAS-6 lacking the self-oligomerization activity, fundamentally deviating from the current paradigm for centriole biogenesis. Moreover, our results show that in human cells, de novo centriole assembly is an error-prone process that generates abnormal centrioles in a significantly higher frequency comparing to canonical duplication. The error rate of de novo assembly, which was estimated from later stages of centrioles, could potentially be underestimated, as it is plausible that the de novo centrioles formed initially are actually much more error-prone, and that over time ninefold symmetric centrioles persist because they are more stable or more efficient to duplicate. In any case, our results suggest that if de novo assembly must be used for centriole production, the structural accuracy may need to be insured or reinforced by other mechanisms.

The expression level of the SAS-6^FL^ or SAS-6^F131E^ in our cell-based assay is higher than the endogenous level of SAS-6 responsible for canonical duplication ([Figure 1F](#fig1){ref-type="fig"}; [Figure 1---figure supplement 1D](#fig1s1){ref-type="fig"}), a condition that may potentially affect the accuracy of de novo centriole assembly. However, as de novo centriole assembly is normally blocked under physiological conditions (for number control), it is unclear what the 'right' level of SAS-6 should be, or if the level really matters that much, when the number control is not a relevant issue for de novo assembly. Consistently, it has been reported that de novo centrioles made of disorganized, or abnormal numbers of MT blades are formed with the endogenous level of SAS-6 ([@bib17]). Conversely, during multiciliogenesis where SAS-6 level is highly up-regulated ([@bib11]), almost every new centriole forms correctly. These results suggest that when cells carry pre-existing centrioles, they could perhaps tolerate a wider range of SAS-6 level for proper structural assembly of centrioles. Numerical control of centriole biogenesis, however, is a different issue, as it is highly sensitive to the sas-6 level ([@bib22]), even in the presence of pre-existing centrioles.

Our results thus lead to an interesting question: Is de novo synthesis a reliable, physiologically relevant pathway for centriole production in animals? Large quantities of centrioles naturally arising from the acentriolar pathway has been reported in planarians ([@bib4]), but whether the same process occurs in vertebrates under normal physiological conditions is unclear. It will be very interesting to see if planarians carefully specify the structural integrity of de novo centrioles, and if so, how the accuracy is achieved in the absence of pre-existing centrioles. In vertebrate somatic cycling cells, the birth of a new centriole is normally given by the pre-existing centriole (canonical duplication), a process known to regulate the number at which newborn centrioles can form. It has led to a belief that de novo assembly would take over the canonical duplication, when large, variable numbers of centrioles are needed, such as in the post-mitotic, multi-ciliated epithelium. Strikingly, a recent report showed that in multi-ciliated epithelia, de novo assembly is not responsible for the production of hundreds of centrioles ([@bib2]); instead, all new centrioles that later form cilia are initiated, directly or indirectly, from the pre-existing centriole, supporting the idea that the presence of pre-existing centrioles has additional roles other than the number control for centriole reproduction. Our results that canonically duplicated centrioles are predominantly free of error, while de novo centriole assembly is error-prone, suggest that perhaps pre-existing centrioles can specify some steps of the assembly process that define the structural integrity of the centriole (e.g. cartwheel assembly), an idea consistent with the template-based model of centriole formation proposed recently ([@bib9]).

Notably, mouse embryos show exceptions that break all the known rules. The mouse embryogenesis starts with a fertilized egg lacking apparent centrioles/centrosomes, and finishes with an intact animal in which nearly all cells carry centrioles that are both numerically and structurally normal ([@bib1]; [@bib10]; [@bib12]; [@bib21]). How acentrosomal cells in mouse embryos escape from p53 dependent elimination acting against acentrosomal mitosis ([@bib5]; [@bib18]; [@bib26]), and how they later form and maintain proper centrioles in the absence of pre-existing centrioles are completely not understood. With our surprising observation that SAS-6 self-oligomerization is not essential for centriole assembly, perhaps other unanticipated mechanisms are specifically involved in centriole biogenesis in early mouse embryos.

Material and methods {#s4}
====================

Cell culture, SAS-6 constructs, and antibodies {#s4-1}
----------------------------------------------

Human telomerase-immortalized retinal pigment epithelial cells (hTERT-RPE1 or RPE1) were cultured in DME/F-12 (1:1) medium supplemented with 10% FBS and 1% penicillin-streptomycin. The expression constructs of the various SAS-6 DMs under the control of tetracycline-inducible promoter were made using the lentiviral vector pLVX-Tight-Puro vector (Clonetech) as described previously ([@bib9]). Antibodies used in this study include anti-α-tubulin (Sigma-Aldrich), anti-HA.11 (Covance), anti-polyglutamylated tubulin (GT-335; Adipogen), anti-pericentrin and CPAP (Proteintech), anti-centrin2 (Millipore), anti-BrdU (AbD Serotec), CEP164 (Novus Biologicals), anti-STIL (Bethyl laboratories, Inc), anti--p53 and hSAS-6 (Santa Cruz Biotechnology; sc-6243, sc-376836 and sc-81431), and anti-CEP135 (abcam, ab75005). The antibody for N-terminal SAS-6 (sc-376836) is a monoclonal antibody raised against amino acids 1--300, with the actual epitope being mapped within amino acids 173--300 ([Figure 1---figure supplement 1D](#fig1s1){ref-type="fig"}). The antibody for C-terminal SAS-6 (sc-81431) is a monoclonal antibody raised against amino acids 404--657, with the epitope being mapped within amino acids 519--657 ([Figure 1F](#fig1){ref-type="fig"}).

CRISPR construction and generation of *SAS6^-/-^; p53^-/-^* acentriolar cells {#s4-2}
-----------------------------------------------------------------------------

RNA-guided targeting of genes in human cells was achieved through coexpression of the Cas9 protein with gRNAs using reagents prepared by the Church group ([@bib19]), which are available from the Addgene (http://www.addgene.org/crispr/church/). The targeting sequence for TP53 and SAS-6 is 5'-GGCAGCTACGGTTTCCGTC-3' and 5'-GTGAAATGCAAAGACTGTG-3', respectively, which were cloned into the gRNA cloning vector (Addgene plasmid \#41824) via the Gibson assembly method (New England Biolabs, Ipswich, MA) as described previously ([@bib19]). To obtain stable acentriolar cells lacking SAS-6, the TP53 gene in RPE1 cells was targeted by the CRISPR method prior to inactivation of SAS-6. Six days after SAS-6 inactivation, we observed that about 10--15% of cells were devoid of centrioles or centrosomes. Pure acentriolar cell lines were subsequently established through clonal propagation from single cells, a process taking additional 4--5 weeks (before these cells were used for experiments), generating a number of independent *SAS-6^-/-^; p53^-/-^*cell lines all behaving similarly (with clone \#1 and \#2 being characterized here). *SAS-6^-/-^; p53^-/-^* cells actively proliferate or divide, but take longer periods of time to go through mitosis ([Figure 1D](#fig1){ref-type="fig"}). For genotyping, the following PCR primers were used: 5'-ATCGGAATTCGGCCAAGTCTCTTACGCCTT-3' and 5'- CTAGTCTAGAATGTGAGCCGGCTTCCTAAC-3' for SASS6 alleles, and 5'- ACGCGGATCCACCCATCTACAGTCCCCCTTG-3' and 5'-CTAGTCTAGAGCATCCCCAGGAGAGATGCT-3' for TP53 alleles. PCR products were cloned and sequenced.

Reconstitution of de novo centriole/centrosome formation {#s4-3}
--------------------------------------------------------

To examine the role of SAS-6 in de novo centriole formation, *SAS-6^-/-^; p53^-/-^* cell lines generated above were infected with lentiviruses carrying various of SAS-6 constructs, and induced to express wild-type or mutant SAS-6 with 50 ng/ml Doxycycline for 16 hr. To examine the function of de novo centrioles to form centrosomes, to duplicate, or ciliate, infected cells were incubated with doxycycline for 3 days, followed by serum starvation if ciliogenesis was to be examined. Isogenic, acentriolar cell lines stably carrying specific SAS-6 expression constructs (SAS-6-expression-ready cells) were isolated and propagated from single cells in the absence of doxycycline, which allow us to directly induce de novo centriole/centrosome formation with doxycycline addition. Our reconstitution of de novo centriole/centrosome formation was successfully done in acentriolar cells infected with viruses and then treated with doxycycline ([Figure 1E](#fig1){ref-type="fig"}; [Figure 1---figure supplement 2C,D](#fig1s2){ref-type="fig"}), or in isogenic, SAS-6-expression-ready cells treated with doxycycline ([Figures 1G,2](#fig1){ref-type="fig"}).

Immunofluorescence and time-lapse microscopy {#s4-4}
--------------------------------------------

Cells were fixed with methanol at −20°C for 5 min. Slides were blocked with 3% bovine serum albumin (w/v) with 0.1% Triton X-100 in PBS before incubating with the indicated primary antibodies. Secondary antibodies were from molecular probes and were diluted 1:500. DNA was visualized using 4′,6-diamidino-2-phenylindole (DAPI; Molecular Probes). Fluorescent images were acquired on an upright microscope (Axio imager; Carl Zeiss) equipped with 100× oil objectives, NA of 1.46, and a camera (ORCA ER; Hamamatsu Photonics). For time-lapse experiments, hTERT-RPE1 cell (wild-type, P53^-/-^ or p53^-/-^; SAS-6^-/-^) were imaged using a Zeiss Axiovert microscope configures with a 10X objective, motorized temperature-controlled stage, environmental chamber, and CO~2~ enrichment system (Zeiss, Germany). Images were acquired and processed by axiovision software (Zeiss, Germany).

Transmission electron microscopy {#s4-5}
--------------------------------

Cells grown on coverslips made of Aclar film (Electron Microscopy Sciences) were fixed in 4% paraformaldehyde and 2.5% glutaraldehyde with 0.1% tannic acid in 0.1 M sodium cacodylate buffer at room temperature for 30 min, postfixed in 1% OsO~4~ in sodium cacodylate buffer for 30 min on ice, dehydrated in graded series of ethanol, infiltrated with EPON812 resin (Electron Microcopy Sciences), and then embedded in the resin. Serial sections (∼90-nm thickness) were cut on a microtome (Ultracut UC6; Leica) and stained with 1% uranyl acetate as well as 1% lead citrate. Samples were examined on JEOL transmission electron microscope. Tomography data was collected using a JEOL 1400 Plus TEM operated at 120 kV. Double tilt series were recorded from --60° to 60° with 1° increments using SerialEM software ([@bib20]). Tomograms were reconstructed using IMOD programs ([@bib16]).

Funding Information
===================

This paper was supported by the following grants:

-   http://dx.doi.org/10.13039/100000002National Institutes of Health GM088253 to Meng-Fu Bryan Tsou.

-   http://dx.doi.org/10.13039/100000048American Cancer Society RSG-14-153-01 to Meng-Fu Bryan Tsou.

-   http://dx.doi.org/10.13039/501100004663Ministry of Science and Technology, Taiwan 103-2320-B-010-046-MY2 to Won-Jing Wang.

We thank N Lampen at MSKCC for assisting the usage of transmission electron microscopy. This work is supported by the National Institutes of Health grants GM088253 and the American Cancer Society RSG-14-153-01-CCG to M-F B Tsou. WJ Wang is supported by the Taiwan Ministry of Science and Technology (MOST 103-2320-B-010-046-MY2).

Additional information {#s5}
======================

The authors declare that no competing interests exist.

WJW, Conception and design, Acquisition of data, Analysis and interpretation of data, Drafting or revising the article, Contributed unpublished essential data or reagents.

DA, Acquired EM tomography, Acquisition of data.

CHK, Acquisition of data.

WNJ, Acquisition of data.

KU, Acquisition of data.

MFBT, Conception and design, Analysis and interpretation of data, Drafting or revising the article, Contributed unpublished essential data or reagents.

10.7554/eLife.10586.012

Decision letter

Stearns

Tim

Reviewing editor

Stanford University

,

United States

eLife posts the editorial decision letter and author response on a selection of the published articles (subject to the approval of the authors). An edited version of the letter sent to the authors after peer review is shown, indicating the substantive concerns or comments; minor concerns are not usually shown. Reviewers have the opportunity to discuss the decision before the letter is sent (see [review process](http://elifesciences.org/review-process)). Similarly, the author response typically shows only responses to the major concerns raised by the reviewers.

Thank you for submitting your work entitled \"De novo centriole formation in human cells is error-prone and does not require SAS-6 self-assembly\" for peer review at *eLife*. Your submission has been favorably evaluated by Randy Schekman (Senior editor), a Reviewing editor, and three reviewers.

The reviewers have discussed the reviews with one another and the Reviewing editor has drafted this decision to help you prepare a revised submission.

Summary:

Centrioles are cylindrical, microtubule-based organelles that form the core of the centrosome and are essential for the formation of cilia and flagella. In cycling cells, centrioles duplicate exactly once in each cell cycle, through the formation of a single new daughter centriole on the wall of each existing mother centriole. The first morphological event in the assembly process is the emergence of a cartwheel structure adjacent to the wall of the mother centriole. SAS-6 proteins are a key structural component of the cartwheel. SAS-6 forms a parallel homodimer that associates laterally through a globular N-terminal domain. Models have shown that the association of the SAS-6 N-terminal domain can generate a ring of nine homodimers and this has been proposed to explain the ninefold symmetrical architecture of the cartwheel.

In this manuscript, Wang et al. test the widely-held assumption that SAS6 self-oligomerization is a necessary step in centriole assembly. The authors produce a p53/SAS6 knockout cell line that lacks centrioles, and subsequently introduce wild type or mutant SAS6 constructs to test which domains of SAS6 are required for de novo centriole assembly. Surprisingly, the authors find that mutants of SAS6 that are unable to undergo self-oligomerization are sufficient for assembling functional centrioles. Interestingly, centrioles that form de novo even in the presence of wild type SAS6 are frequently found to have structural defects. Most surprisingly, de novo centrioles assembled with SAS6 fragments that are unable to self-associate were capable of undergoing canonical duplication. Since the same SAS6 fragments are not capable of supporting the duplication of existing centrioles, the authors suggest that existing centrioles may play a role in shaping the structural integrity of procentrioles.

Essential revisions:

1\) The interpretation of the work depends on the nature of the SAS6 deletion allele in the RPE1 cells used. If, for example, a fragment of protein is made, this would critically alter the interpretation. Thus, the authors should provide additional characterization of the p53/SAS6 knockout RPE1 cells that form the basis of this paper. Specifically, the DNA sequence of the edited SAS6 alleles should be provided, and possible predicted truncated products indicated. Furthermore, the authors should provide the product number for their SAS6 antibody, and describe the antigen that was used to make it. Ideally, they would test for the presence of SAS6 RNA, and test several SAS6 polyclonal antibodies on their knockout cell line to assure that a SAS6 fragment is not being produced from the putative knockout allele. The history of mammalian genetics is replete with examples of alleles thought to be null that were not indeed null -- this is a critical point.

2\) At the outset the authors don\'t quantify how the p53^-/-^; SAS6^-/-^ cells lose centrioles or show that they completely lack centrioles. Importantly, it is also unclear how long the cells used in these experiments have been cultured in the absence of centrioles and p53 before the expression of the Sas-6 constructs is induced. The authors state that clonal cell lines were derived for all constructs, but it is not clear how many were tested and how variable the expression levels were between different clonal lines. These points should be addressed in the text.

3\) The size and number of de novo centrioles induced by SAS6 construct expression is not quantified or statistically analyzed (the authors show a single image of a few cells for each construct). This is important, as this seems to be quite variable and the authors make several statements implying that all of these de novo centrioles can duplicate and form cilia, which seems surprising given this variation. The authors should explain their criteria for scoring something as a centriole/centrosome/cilia, and show graphs of the number and size distribution of these organelles for all the expression constructs tested. This is symptomatic of a general problem of making statements that are too strong for the data presented. For example, the authors consistently state that all the de novo structures they observe are normal centrioles that can form normal centrosomes and cilia, but this seems very unlikely given the variation in the size and number of these structures formed in each cell (see [Figure 1G](#fig1){ref-type="fig"}). In the text, for example, the authors state that \"all these de novo centrioles\" could mature properly by acquiring distal appendages, and support ciliogenesis upon G1 arrest. Are the authors really claiming that all of these structures form normal cilia? The cilia shown in [Figure 2B](#fig2){ref-type="fig"} look quite variable in size and number. As noted above, it would require proper quantitative serial section EM to prove these points, and the authors already know from their EM analysis that some of these structures are not normal, even without such quantitation. Importantly, even if these structures look normal at the EM level, it does not mean they are fully functional. The authors are urged to be more cautious here and to perhaps only claim that morphologically normal centriole-like structures can be formed in the presence of these constructs, rather than implying that all these de novo structures will form completely normal centrioles, centrosomes and cilia.

4\) As the authors note, it is surprising that the majority of de novo centrioles formed in the presence of the SAS-6 constructs that cannot self-assemble through the head group have a normal structure, and this is the major point of the paper. The lack of quantitation in some of the EM experiments makes this difficult to assess. This is particularly important because it seems plausible that during the early stages of de novo assembly the process is actually very error-prone and that over time 9-fold symmetric centrioles persist because they are more stable (and perhaps cells with 9-fold symmetric centrioles are more viable). The authors should at least consider this possibility, especially in light of the Lambrus et al. (2015) paper, which would support this idea.

5\) The authors should quantify by how much these SAS6 constructs are overexpressed, as the overexpression of SAS6 has previously been shown to drive the de novo formation of abnormal centriole-like-structures in fly eggs (Rodrigues-Martins et al., 2007 and Peel et al., 2007). From the single blot shown, it seems that the proteins are expressed at close to normal levels, but this should be quantified, and some estimate of the experimental variability should be given. This should also be assessed for all the experimental conditions tested (e.g. the authors don\'t assess SAS6 protein levels in the experiments where the cells are extensively arrested in S-phase or G1). This potential caveat to the interpretation of these results should be discussed.

6\) The authors claim the de novo centrioles formed with any of the Sas-6 constructs can all undergo canonical duplication. Others have shown that when centrioles are re-introduced into cells lacking centrioles there is a burst of de novo assembly, but the cell population then stabilizes its centriole numbers and seems to revert to normal canonical duplication -- e.g. Wong et al., 2015 (this paper should be referenced) and Lambrus et al., 2015. It would be very informative to know whether this happens for the constructs tested here. If the WT constructs can support the return to canonical duplication, while the F131E and DM4 constructs cannot, this would suggest that the mutant constructs can support some level of error-prone de novo assembly, but cannot support canonical duplication. Although it is not essential that the authors perform this experiment for the revision, if they have the data available, they would strengthen the paper.

7\) Related to this last point, it is surprising that the authors don\'t discuss in any detail why their results might differ from those reported by other groups. One possibility is that they are assessing error-prone de novo assembly from a cell line that started with no centrioles, while the other groups were starting from cell lines that had centrioles and where they depleted the endogenous SAS6 in the presence of RNAi resistant forms of SAS6 that could not multimerize. Moreover, they should mention the recent observation that a form of fly SAS6 carrying the equivalent to the F131E mutation could also support the formation of some centriole-like structures in vivo (although these were not examined at the EM level -- Cottee et al., 2015).

8\) The authors frame their paper as a contrast between the self-assembly model and the templating model, but the two models are not mutually exclusive. As the authors note, it is surprising that mutants that are self-assembly deficient are remarkably efficient in de novo centriole formation, but this does not necessarily prove the self-assembly model wrong. Purified proteins may be self-assembly deficient in vitro, but be assisted by other proteins (restoring some oligomerization) in vivo. The templating model is attractive, but it does not readily explain the importance of the C-terminal end domains revealed in the de novo assembly system used here, where there is no mother centriole lumen with which to interact. The authors should adopt a more conciliatory tone with regard to the two previously proposed models. Once again, these are not mutually exclusive, and the present data, although very interesting and worthy of publication, do not allow us to identify a \"winner.\"

10.7554/eLife.10586.013

Author response

We would like to thank the reviewers and editors for the positive notes and critical suggestions. We have revised the manuscript accordingly, and provided a separate file with tracked changes. Significant changes are itemized below, followed by our point-by-point responses that address reviewers' concerns.

New items:

1\) [Figure 1---figure supplement 1](#fig1s1){ref-type="fig"}: detailed characterization of the *sas-6^-/-^; p53^-/-^* cell lines (clone \#1 and \#2), including genotyping, determination of the (exogenous) SAS-6 expression level, and mapping of the SAS-6 antibodies (N- or C-terminal) we used.

2\) [Figure 1---figure supplement 2](#fig1s2){ref-type="fig"}: characterization of de novo centriole/centrosome formation in clone \#2 *SAS-6^-/-^; p53^-/-^* cell line.

3\) [Figure 2---figure supplement 1](#fig2s1){ref-type="fig"}: the original Supplemental Figure 1.

4\) [Figure 4A & C](#fig4){ref-type="fig"}: during the revision, we found that the [images 4A](#fig4){ref-type="fig"}-\#6 and 4C-\#3 in the original figure were mistakenly swapped. These images, which look quite similar, were misplaced during imaging preparation.

5\) [Figure 4D](#fig4){ref-type="fig"}: quantification of the width (outer diameter) of canonical and de novo centrioles.

6\) Materials and methods: new details were added to subsection "CRISPR construction and generation of *SAS6^-/-^; p53^-/-^* ancentriolar cells". In addition, a new subsection titled "Reconstitution of de novo centriole formation" is added to the Materials and methods, describing how we induce de novo centriole formation in clonal or non-clonal cell populations.

7\. Other changes are detailed below in our point-by-point response.

*Essential revisions:*

*1) The interpretation of the work depends on the nature of the SAS6 deletion allele in the RPE1 cells used. If, for example, a fragment of protein is made, this would critically alter the interpretation. Thus, the authors should provide additional characterization of the p53/SAS6 knockout RPE1 cells that form the basis of this paper. Specifically, the DNA sequence of the edited SAS6 alleles should be provided, and possible predicted truncated products indicated. Furthermore, the authors should provide the product number for their SAS6 antibody, and describe the antigen that was used to make it. Ideally, they would test for the presence of SAS6 RNA, and test several SAS6 polyclonal antibodies on their knockout cell line to assure that a SAS6 fragment is not being produced from the putative knockout allele. The history of mammalian genetics is replete with examples of alleles thought to be null that were not indeed null -- this is a critical point.*

We have now provided suggested characterizations on two independent *sas-6^-/-^; p53^-/-^* cell lines (clone \#1 and \#2). Both clones behave similarly for de novo centriole or centrosome formation ([Figure 1](#fig1){ref-type="fig"} and [Figure 1---figure supplement 2](#fig1s2){ref-type="fig"}); detailed EM analyses of de novo centrioles were done only with cell lines derived from clone \#1.

DNA sequence analyses showed that each allele of the SAS-6 gene in either clone \#1 or \#2 was edited to carry frameshift mutations in the beginning of the coding region ([Figure 1---figure supplement 1A](#fig1s1){ref-type="fig"}), predicted to produce severely truncated products consisting of only 19 or 23 amino acids in clone \#1 or \#2 respectively. Consistently, no SAS-6 signal can be detected by western blot using antibodies against either the N- or C-terminal region of SAS-6 ([Figure 1B](#fig1){ref-type="fig"}; [Figure 1---figure supplement 1C](#fig1s1){ref-type="fig"}). The antibody for N-terminal SAS-6, from Santa Cruz (sc-376836), is a monoclonal antibody raised against amino acids 1-300, with the actual epitope being mapped within amino acids 173-300 ([Figure 1---figure supplement 1D](#fig1s1){ref-type="fig"}; Materials and methods). The antibody for C-terminal SAS-6, from Santa Cruz (sc-81431), is a monoclonal antibody raised against amino acids 404-657, with the epitope being mapped within amino acids 519-657 ([Figure 1F](#fig1){ref-type="fig"}; Materials and methods). We have also tried several other polyclonal antibodies raised against the N-terminus of SAS-6, including Novus (NB100-93342), Bethyl Labs (A301-801A), and Santa Cruz (sc-98506), but none of them worked in our hands. In addition to SAS-6, we also found and mapped frameshift mutations in TP53 alleles, leading to loss of p53 function ([Figure 1---figure supplement 1B](#fig1s1){ref-type="fig"}).

*2) At the outset the authors don\'t quantify how the* p53^-/-^; SAS6^-/-^ *cells lose centrioles or show that they completely lack centrioles. Importantly, it is also unclear how long the cells used in these experiments have been cultured in the absence of centrioles and p53 before the expression of the Sas-6 constructs is induced. The authors state that clonal cell lines were derived for all constructs, but it is not clear how many were tested and how variable the expression levels were between different clonal lines. These points should be addressed in the text.*

a\) More information regarding how we isolate acentriolar cell lines has been added (in the main text and Materials and methods). In brief, six days after SAS-6 inactivation by CRISPR treatments (in p53^-/-^ background), we observed that 10-15% of cells in the population were devoid of centrioles or centrosomes. Pure acentriolar cell lines were further isolated through clonal propagation from single cells, a process taking additional four to five weeks, before these cells were used for reconstitution experiments (see b) below). That is, our acentriolar cell lines have been devoid of SAS-6 proteins or centrioles for at least 6 weeks or longer before they were used for reconstitution experiments.

b\) Regarding whether our observation occurs only in one particular line (due to clonal variation), we have now made it clear in the text and Materials and methods that de novo centriole assembly could be efficiently driven by FL, F131E, DM2, and DM4 in either mixed or isogeneic cell populations. That is, when the two independent SAS-6^-/-^ cell lines (clone \#1 and \#2) were infected with lentivirus carrying DOX-inducible SAS-6 constructs (FL, F131E, DM2, or DM4) and incubated with DOX, we observed de novo centriole/centrosome formation in every infected cells expressing detectable SAS-6 ([Figure 1E](#fig1){ref-type="fig"}; [Figure 1---figure supplement 2](#fig1s2){ref-type="fig"} C, D). Based on these results, we then isolated stable acentriolar cell lines carrying different SAS-6 constructs in the absence of DOX (SAS-6-expression-ready cells), and used these isogenic lines for subsequent reconstitution experiments for a better control on timing and protein expression. Importantly, again, the ability of FL, F131E, DM2, or DM4 to drive de novo centriole formation is consistently seen in both isogenic and non-isogenic conditions.

c\) The SAS-6 expression level in each isogeneic cell line we used has now been quantified and shown ([Figure 1F](#fig1){ref-type="fig"} and [Figure 1---figure supplement 1D](#fig1s1){ref-type="fig"}), which is somewhat higher than the endogenous level of SAS-6 that is responsible for canonical duplication. Note that the "proper" level of SAS-6 for de novo centriole assembly is unknown, as in human body, no known de novo assembly pathway exists under physiological conditions (our discovery here may explain why it shouldn't exist). Please see the response 5a) below for more discussion.

*3) The size and number of de novo centrioles induced by SAS6 construct expression is not quantified or statistically analyzed (the authors show a single image of a few cells for each construct). This is important, as this seems to be quite variable and the authors make several statements implying that all of these de novo centrioles can duplicate and form cilia, which seems surprising given this variation. The authors should explain their criteria for scoring something as a centriole/centrosome/cilia, and show graphs of the number and size distribution of these organelles for all the expression constructs tested. This is symptomatic of a general problem of making statements that are too strong for the data presented. For example, the authors consistently state that all the de novo structures they observe are normal centrioles that can form normal centrosomes and cilia, but this seems very unlikely given the variation in the size and number of these structures formed in each cell (see [Figure 1G](#fig1){ref-type="fig"}). In the text, for example, the authors state that \"all these de novo centrioles\" could mature properly by acquiring distal appendages, and support ciliogenesis upon G1 arrest. Are the authors really claiming that all of these structures form normal cilia? The cilia shown in [Figure 2B](#fig2){ref-type="fig"} look quite variable in size and number. As noted above, it would require proper quantitative serial section EM to prove these points, and the authors already know from their EM analysis that some of these structures are not normal, even without such quantitation. Importantly, even if these structures look normal at the EM level, it does not mean they are fully functional. The authors are urged to be more cautious here and to perhaps only claim that morphologically normal centriole-like structures can be formed in the presence of these constructs, rather than implying that all these de novo structures will form completely normal centrioles, centrosomes and cilia.*

We apologize for our ambiguous writing. We absolutely did not mean to say that every de novo centriole formed in our assay could mature and support ciliogenesis. Our intention was to indicate that *all* SAS-6 constructs that drive de novo centriole assembly, including F131E & DM4, can produce centrioles capable of supporting ciliogenesis (or duplication and centrosome formation). This is supported by both IF (with centriole/PCM/cilia markers), and EM. We have fixed our writing to make it very clear that only some (not all) of the de novo centrioles can duplicate and ciliate.

The number of de novo centriole formed in each cell is variable within the population for all relevant SAS-6 constructs. We think this is the nature of de novo assembly, and decided not to focus on it, as the number can be affected by many (known or unknown) factors that could not be tightly controlled in our assay. Our main point in this study is that every SAS-6^-/-^ cell can produce some numbers of de novo centrioles when certain SAS-6 mutants are re-introduced.

*4) As the authors note, it is surprising that the majority of de novo centrioles formed in the presence of the SAS-6 constructs that cannot self-assemble through the head group have a normal structure, and this is the major point of the paper. The lack of quantitation in some of the EM experiments makes this difficult to assess. This is particularly important because it seems plausible that during the early stages of de novo assembly the process is actually very error-prone and that over time 9-fold symmetric centrioles persist because they are more stable (and perhaps cells with 9-fold symmetric centrioles are more viable). The authors should at least consider this possibility, especially in light of the Lambrus et al. (2015) paper, which would support this idea.*

Thanks for the suggestion; we have included it in the Discussion.

*5) The authors should quantify by how much these SAS6 constructs are overexpressed, as the overexpression of SAS6 has previously been shown to drive the de novo formation of abnormal centriole-like-structures in fly eggs (Rodrigues-Martins et al., 2007 and Peel et al., 2007). From the single blot shown, it seems that the proteins are expressed at close to normal levels, but this should be quantified, and some estimate of the experimental variability should be given. This should also be assessed for all the experimental conditions tested (e.g. the authors don\'t assess SAS6 protein levels in the experiments where the cells are extensively arrested in S-phase or G1). This potential caveat to the interpretation of these results should be discussed.*

a\) We have provided SAS-6 quantification, shown in [Figure 1F](#fig1){ref-type="fig"} and [Figure 1---figure supplement 1D](#fig1s1){ref-type="fig"}. The western blot was done with SAS-6^-/-^ cells inducibly expressing various SAS-6 mutants for 3 days, during which cells were allowed to proliferate. This is the condition and time point where we analyzed centrioles with EM. The expression levels of FL and F131E are similar to each other, but both slightly higher than the endogenous SAS-6 seen in normal RPE1 cells. The potential caveat of SAS-6 over-expression has been included in the Discussion. However, as de novo centriole assembly is normally blocked under physiological conditions (for number control), we really do not known what the "right" level of SAS-6 should be for this pathway, and not sure whether the level matters that much, especially when the number control is not a relevant issue for de novo assembly. Consistently, it has been reported that de novo centrioles made of abnormal numbers of MT blades are formed with endogenous levels of SAS-6 (La Terra et al., 2005). Moreover, during multiciliogenesis where the SAS-6 level is highly up-regulated, almost every new centriole still forms correctly, suggesting that when cells carry preexisting centrioles, they could perhaps tolerate a wider range of SAS-6 level for proper structural assembly of centrioles. Numerical control of centriole biogenesis, however, is a different story, as it is highly sensitive to the sas-6 level (Strnad et al., 2007), even in the presence of preexisting centrioles. This is also included in the Discussion.

b\) The structures formed in unfertilized fly eggs upon overexpression of SAS-6 indeed carry some centriole-like features at the IF/LM level (e.g. able to recruit some centriolar or PCM markers), but at the EM level, they are not centrioles. Unlike cycling cells, unfertilized eggs naturally do not support centriole assembly, and are unique in many other ways; we are reluctant to compare these two systems as it is not the subject of this study, but we clearly show that normal looking centrioles capable of duplication and ciliation can form in our reconstitution assay.

*6) The authors claim the de novo centrioles formed with any of the Sas-6 constructs can all undergo canonical duplication. Others have shown that when centrioles are re-introduced into cells lacking centrioles there is a burst of de novo assembly, but the cell population then stabilizes its centriole numbers and seems to revert to normal canonical duplication -- e.g. Wong et al., 2015 (this paper should be referenced) and Lambrus et al., 2015. It would be very informative to know whether this happens for the constructs tested here. If the WT constructs can support the return to canonical duplication, while the F131E and DM4 constructs cannot, this would suggest that the mutant constructs can support some level of error-prone de novo assembly, but cannot support canonical duplication. Although it is not essential that the authors perform this experiment for the revision, if they have the data available, they would strengthen the paper.*

a\) We apologize for missing the key reference, and have now included it.

b\) We examined centriole duplication 3 days after induction SAS-6 expression, and saw that most cells had a high number of centrioles/centrosomes due to the initial burst of de novo assembly, and more importantly, most of these centrioles could duplicate (based on STIL & centrin doublet staining) regardless of whether they were derived from FL, F131E or DM4. Similar results were also seen by EM. We do notice that centriole numbers drop significantly after a long-term culture, but we are not sure whether this is due to an efficiency issue (i.e. less centrioles are easier to maintain), or alternatively, due to a fitness issue (i.e. a selection against the survival of cells carrying higher numbers of centrioles). This question is very interesting but complicated, requires additional careful investigations, and thus should be answered in a different paper. Our goal is to address whether FL, F131E or DM4 derived centrioles can duplicate, and the answer is clearly yes for at least a significant fraction of centrioles at day 3 (based on IF and EM).

*7) Related to this last point, it is surprising that the authors don\'t discuss in any detail why their results might differ from those reported by other groups. One possibility is that they are assessing error-prone de novo assembly from a cell line that started with no centrioles, while the other groups were starting from cell lines that had centrioles and where they depleted the endogenous SAS6 in the presence of RNAi resistant forms of SAS6 that could not multimerize. Moreover, they should mention the recent observation that a form of fly SAS6 carrying the equivalent to the F131E mutation could also support the formation of some centriole-like structures in vivo (although these were not examined at the EM level -- Cottee et al., 2015).*

a\) Similar to the reviewers' idea, we did propose that preexisting centrioles have some active, dominant roles in guiding canonical duplication (at the end of [Figure 2](#fig2){ref-type="fig"} result). We think this idea could perhaps explain why F131E or DM4 can support the duplication of F131E- or DM4-derived centrioles, respectively ([Figure 2C,D](#fig2){ref-type="fig"}), but not wild-type SAS-6-derived centrioles (Fong et al., 2014; Kitagawa et al., 2011; van Breugel et al., 2011). That is, only F131E- or DM4-derived centrioles but not WT centrioles can use SAS-6^F131E^ or SAS-6^DM4^, respectively, to duplicate.

b\) The paper by Cottee et al. has been added.

*8) The authors frame their paper as a contrast between the self-assembly model and the templating model, but the two models are not mutually exclusive. As the authors note, it is surprising that mutants that are self-assembly deficient are remarkably efficient in de novo centriole formation, but this does not necessarily prove the self-assembly model wrong. Purified proteins may be self-assembly deficient in vitro, but be assisted by other proteins (restoring some oligomerization) in vivo. The templating model is attractive, but it does not readily explain the importance of the C-terminal end domains revealed in the de novo assembly system used here, where there is no mother centriole lumen with which to interact. The authors should adopt a more conciliatory tone with regard to the two previously proposed models. Once again, these are not mutually exclusive, and the present data, although very interesting and worthy of publication, do not allow us to identify a \"winner.\"*

The two main points of this study are (i) SAS-6 self-oligomerization (but not self-assembly of other proteins, or self-assembly in general) is not essential for centriole formation, and (ii) de novo but not canonical centriole assembly is error prone. Both points are clearly stated in the title, Abstract, and Results; no other points beyond these are concluded. While we are not sure which statements the reviewers were referring to, we have removed any irrelevant words that may potentially cause misunderstanding.

In the Discussion, however, we feel that it is necessary to discuss how the template-based model can fit in with the new results we have discovered here.
